

STRIDES PHARMA CANADA INC.
BALANCE SHEET AS AT MARCH 31, 2022

		Amount in CAD 31-Mar-22	Amount in CAD 31-Mar-21
A ASSETS			
I Non-current assets			
	(a) Property, plant and equipment	1,092,335	3,993
	(b) Intangibles assets under development	1,482,139	298,866
	(c) Financial assets		
	(i) Investments	3,803,195	3,803,196
	Total non-current assets	6,377,669	4,106,055
I Current assets			
	(a) Inventories	869,314	678,021
	(a) Financial assets		
	(i) Trade receivables	305,256	494,361
	(ii) Cash and cash equivalents	169,188	231,562
	(b) Other current assets	86,883	793,986
	Total current assets	1,430,641	2,197,930
	TOTAL ASSETS	7,808,310	6,303,985
B EQUITY AND LIABILITIES			
I Equity			
	(a) Equity share capital	1,000	1,000
	(b) Other equity	6,410,206	5,111,141
	Total Equity	6,411,206	5,112,141
II Liabilities			
1 Current liabilities			
	(a) Financial liabilities		
	(i) Trade payables	170,597	454,780
	(ii) Other financial liabilities	1,032,559	597,340
	(b) Provisions	193,948	139,724
	Total current liabilities	1,397,104	1,191,844
	TOTAL EQUITY AND LIABILITIES	7,808,310	6,303,985

STRIDES PHARMA CANADA INC.
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2022

	Particulars	Note No.	Amount in CAD	
			31-Mar-22	31-Mar-21
1	Revenue from operations	10	2,097,112	624,458
2	Other Income	11	74,628	186,145
3	Total Revenue (1+2)		2,171,739	810,603
4	Expenses			
	(a) Cost of goods sold		350,755	299,401
	(b) Employee benefits expense	12	371,343	527,468
	(c) Finance costs	13	4,046	4,181
	(d) Depreciation and amortisation expense		126,527	1,130
	(e) Other expenses	14	986,029	539,585
	Total expenses		1,838,700	1,371,765
5	Profit / (Loss) before exceptional items and taxes (3-4)		333,039	(561,162)
6	Exceptional Item		260,974	73,289
7	Profit / (Loss) before taxes (5+6)		72,065	(634,451)
8	Tax Expense:			
	(1) Current tax		-	-
	(2) Deferred tax		-	-
	Total tax expenses		-	-
9	Profit / (Loss) for the year after tax		72,065	(634,451)

STRIDES PHARMA CANADA INC.
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED MARCH 31, 2022

(A) Equity share capital

Particulars	Amount in CAD
Balance as at March 31, 2021	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2022	1,000

(B) Other equity

Amount in CAD

Particulars	Share application money pending allotment	Reserves and surplus	Total
		Retained earnings	
Balance as at March 31, 2021	6,112,264.56	(1,501,124)	4,611,141
Application money received during the year	1,727,000	-	1,727,000
Profit/loss for the year	-	72,065	72,065
Balance as at March 31, 2022	7,839,265	(1,429,059)	6,410,206

STRIDES PHARMA CANADA INC.

Notes forming part of financial statement

Note

No.

1 Non current investments	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Pharmapar Inc	869,314	3,803,196
Total	869,314	3,803,196

2 Trade receivables	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Unsecured		
Considered good	305,256	494,361
Total	305,256	494,361

3 Cash and cash equivalents	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Cash in hand		
Balances with banks:		
In current accounts	169,188	231,562
Total	169,188	231,562

4 Other current assets	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Unsecured, considered good		
Loans and advances to Group entities	-	767,574
Balances with government authorities	-	21,479
Prepaid Expenses	86,883	4,934
Total	86,883	793,986

5 Share capital	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Issued, subscribed and fully paid-up		
Equity share capital	1,000	1,000
Total	1,000	1,000

6 Reserves and surplus	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Share Application money Pending Allotment	7,839,265	6,112,265
	7,839,265	6,112,265
Surplus in statement of profit and loss		
Opening balance	(1,501,124)	(939,962)
Add: Profit / (Loss) for the year	72,065	(561,162)
Closing balance	(1,429,059)	(1,501,124)
Total	6,410,206	4,611,141

7 Trade payables	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Trade payable	170,597	454,780
Total	170,597	454,780

8 Other Current financial Liabilities	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Payable to group entities	980,069	576,396
Other payables:		
- Statutory remittances	52,491	20,943
Total	1,032,559	597,340

9 Provisions	Amount in CAD	
Particulars	31-Mar-22	31-Mar-21
Provision for expenses	193,948	139,724
Total	193,948	139,724

STRIDES PHARMA CANADA INC.
Notes forming part of financial statement

Note

No.

10 Revenue from operations **Amount in CAD**

Particulars	31-Mar-22	31-Mar-21
Sale of Product	2,097,112	624,458
Total	2,097,112	624,458

11 Other Income **Amount in CAD**

Particulars	31-Mar-22	31-Mar-21
Other Income	15,944	41,982
Exchange fluctuation gain	-	32,092
Sundry balance written back	-	6,982
Interest Income	58,684	105,088
Total	74,628	186,145

12 Employee Benefit Expenses **Amount in CAD**

Particulars	31-Mar-22	31-Mar-21
Salaries and wages	371,343	527,468
Total	371,343	527,468

13 Finance cost **Amount in CAD**

Particulars	31-Mar-22	31-Mar-21
Finance Cost	4,046	4,181
Total	4,046	4,181

14 Other expenses **Amount in CAD**

Particulars	31-Mar-22	31-Mar-21
Freight and forwarding	41,903	8,422
Coverion & processing charges	156,847	117,333
Consumables	44,238	58,928
Director sitting fees	-	20,000
Commission	2,615	559
General Expenses	-	23,436
Rates & Taxes	101,207	132,945
Repairs & Maintenance	7,239	314
Insurance	3,843	1,977
Conveyance & Travelling	554	7,277
Advertising & selling expenses	54,912	79,082
Membership fees and subcription	-	17,759
Net loss on foreign currency transactions	43,074	-
Professional fees	279,217	70,330
Miscellaneous Expense	250,379	1,223
Total	986,029	539,585